The commercial availability of Airsupra in the U.S. is likely to have a positive impact on AstraZeneca's short-term revenue as it opens up a new revenue stream from a large market. The FDA approval indicates a strong regulatory endorsement, which can increase physician and patient trust in the product, potentially leading to higher sales. As this is a new product launch, it is significant for the company and investors.